Sava is developing a sensor technology aimed at replacing fingerstick glucose testing. The company has secured $36 million in Series B funding, led by Ascensia, to support the commercialization and distribution of its products in Europe. Their goal is to obtain CE approval for insulin dosing without fingerstick checks within 18-24 months.

Total raised
Undisclosed
tracked to date
Latest round
Series B
Oct 9, 2026
Known investors
2
led by Ascensia

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United Kingdom.

Claim this profile →

🏆 Featured in Datapile’s Q4 2026 UK Funding Report

Read the Q4 2026 UK report →
Add this badge to your site
<a href="https://datapile.co/reports/q4-2026-uk-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q4 2026 UK Funding Report</a>

Funding history

  1. 1
    $36M Series BSeries BOct 9, 2026

    Led by Ascensia

    Announcement ↗

Founder

Renato Circi
Renato Circi

Investors in Sava

Backers from this company's tracked funding rounds.

  • AAscensiaLead investorVC firm
  • PPHC HoldingsVC firm

Sava in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile